A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

About This Trial

This study is testing whether adding metformin, a common diabetes medicine, and turmeric to hormone therapy can help delay the return of prostate cancer.
It is open to adults who previously had surgery or radiation for prostate cancer and are now seeing their PSA levels rise again.
If you choose to join, you will need to take the study pills with your meals, keep a daily pill diary, and pause any other vitamin or mineral supplements you currently take.
You should also know that participation involves providing regular blood and stool samples and completing surveys about your quality of life.

The goal of this clinical trial is to assess the feasibility of adding a combination of metformin and turmeric as part of a nutritional intervention regimen to the current Standard of Care, namely, intermittent Androgen Deprivation Therapy (iADT), for patients with castration sensitive biochemical progressive prostate cancer.
The main objectives are: - Assess the feasibility of the study population and enrollment. - Evaluate time to PSA relapse with nutritional intervention on iADT.
Participants who are receiving iADT will be dispensed Metformin and turmeric and complete a pill diary.
Participants will also have blood and stool samples collected and complete quality of life questionnaires.
The long-term goal is to further assess the efficacy and safety of this nutritional regimen and the roles of metabolic syndrome, microenvironment/microbiome, and genomic vs epigenomic profiles in the care of these patients through a clinical trial.

Age Range: 18 - 100 years
Gender: Male
Who This Trial is For: This study is testing whether adding metformin, a common diabetes medicine, and turmeric to hormone therapy can help delay the return of prostate cancer.

Full Eligibility Criteria

Inclusion Criteria

18 years of age or older.
History of prior prostatectomy and/or radiation therapy to the prostate.
Currently have rising PSA levels ≥ 0.2 ng/ml if they have undergone radical prostatectomy, or a PSA ≥ nadir + 2 if they have received only radiotherapy. Patients who were not offered salvage radiotherapy as an alternative treatment will be considered ineligible (due to a high PSA, other medical concerns).
Currently have at least 2 consecutively rising serum PSA levels more than 1 week apart
Currently have a PSA doubling time 150 ng/dl at time of consent.
Prior ADT (including iADT) for up to 24 months in association with definitive treatment is permitted if completed at least 12 months prior to consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
Willing to take study agents at the dose specified with meals.
Willing to discontinue current vitamin/mineral supplements and use only those provided by study. Herbal supplements may still be used.

Exclusion Criteria

Current Chronic Lymphocytic Leukemia (CLL), Monoclonal Gammopathy of Unknown Significance (MGUS), Renal Cell Carcinoma (RCC) or another cancer requiring active treatment. Indolent or stable malignancies such as non-melanoma skin cancers are allowed.
Any active or deteriorating liver or renal disease, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C or bone marrow deficiency.
Any history of allergic reactions attributed to turmeric, metformin, or other compounds of similar chemical or biologic compositions.
History of lactic acidosis or risk factors for lactic acidosis (e.g., renal impairment, concomitant use of carbonic anhydrase inhibitors such as topiramate, hypoxic states such as acute congestive heart failure, excessive alcohol intake, and hepatic impairment).
Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.